AbCellera Biologics Inc. (ABCL) News

AbCellera Biologics Inc. (ABCL): $4.83

0.12 (+2.55%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add ABCL to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#169 of 345

in industry

Filter ABCL News Items

ABCL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ABCL News Highlights

  • ABCL's 30 day story count now stands at 11.
  • Over the past 21 days, the trend for ABCL's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • BEAT, DRUG and SITC are the most mentioned tickers in articles about ABCL.

Latest ABCL News From Around the Web

Below are the latest news stories about ABCELLERA BIOLOGICS INC that investors may wish to consider to help them evaluate ABCL as an investment opportunity.

AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023

VANCOUVER, British Columbia, November 16, 2023--AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023

Yahoo | November 16, 2023

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

VANCOUVER, British Columbia, November 03, 2023--AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

Yahoo | November 3, 2023

AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2023 Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2023 Earnings Call Transcript November 2, 2023 AbCellera Biologics Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.14. Operator: Good afternoon, and welcome to AbCellera’s Third Quarter 2023 Business Update Conference Call. My name is Kate, and I will facilitate the audio portion of today’s interactive broadcast. [Operator […]

Yahoo | November 3, 2023

Q3 2023 Abcellera Biologics Inc Earnings Call

Q3 2023 Abcellera Biologics Inc Earnings Call

Yahoo | November 3, 2023

Prelude Therapeutics Inc (PRLD) Reports Q3 Financial Results and Strategic Pipeline Progress

Company prioritizes SMARCA2 degrader and CDK9 inhibitor programs, reports cash runway into 2026

Yahoo | November 3, 2023

AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript

Image source: The Motley Fool. AbCellera Biologics (NASDAQ: ABCL)Q3 2023 Earnings CallNov 02, 2023, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon, and welcome to AbCellera's third quarter 2023 business update conference call.

Yahoo | November 3, 2023

AbCellera Biologics Inc (ABCL) Reports Q3 2023 Earnings: Revenue Drops to $7 Million

Company's Net Loss Widens to $0.10 Per Share

Yahoo | November 2, 2023

AbCellera Reports Q3 2023 Business Results

VANCOUVER, British Columbia, November 02, 2023--AbCellera Reports Q3 2023 Business Results

Yahoo | November 2, 2023

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

WILMINGTON, Del. & VANCOUVER, British Columbia, November 01, 2023--Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

Yahoo | November 1, 2023

AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023

VANCOUVER, British Columbia, October 31, 2023--AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023

Yahoo | October 31, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!